Targeted treatments in autism and fragile X syndrome
Open accessThe DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Abstract
Autism is a neurodevelopmental disorder consisting of a constellation of symptoms that sometimes occur as part of a complex disorder characterized by impairments in social interaction, communication and behavioral domains. It is a highly disabling disorder and there is a need for treatment targeting the core symptoms. Although autism is accepted as highly heritable, there is no genetic cure at this time. Autism is shown to be linked to several genes and is a feature of some complex genetic disorders, including fragile X syndrome (FXS), fragile X premutation involvement, tuberous sclerosis and Rett syndrome. The term autism spectrum disorders (ASDs) covers autism, Asperger syndrome and pervasive developmental disorders (PDD-NOS) and the etiologies are heterogeneous. In recent years, targeted treatments have been developed for several disorders that have a known specific genetic cause leading to autism. Since there are significant molecular and neurobiological overlaps among disorders, targeted treatments developed for a specific disorder may be helpful in ASD of unknown etiology. Examples of this are two drug classes developed to treat FXS, Arbaclofen, a GABAB agonist, and mGluR5 antagonists, and both may be helpful in autism without FXS. The mGluR5 antagonists are also likely to have a benefit in the aging problems of fragile X premutation carriers, the fragile X –associated tremor ataxia syndrome (FXTAS) and the Parkinsonism that can occur in aging patients with fragile X syndrome. Targeted treatments in FXS which has a well known genetic etiology may lead to new targeted treatments in autism.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dawson, G., Rogers, S., Munson, J., Smith, M., Winter, J., Greenson, J., Donaldson, A., & Varley, J. (2010) · Pediatrics · doi:10.1542/peds.2009-0958 · Cited by 2,835 · cited 1×
“…all legal disclaimers that apply to the journal pertain. ark-text $w aterm ark-text $w aterm ark-text significantly helpful in children with ASD (Dawson et al., 2010), there are no pharmacological cures for these very impairing conditions that affect social interaction, communication, and…”
BackgroundFMRP Stalls Ribosomal Translocation on mRNAs Linked to Synaptic Function and Autism
Darnell, J. C., Van Driesche, S. J., Zhang, C., Hung, K. Y. S., Mele, A., Fraser, C. E., Stone, E. F., Chen, C., Fak, J. J., Chi, S. W., et al. (2011) · Cell · doi:10.1016/j.cell.2011.06.013 · Cited by 2,072 · cited 1×
“Many of the messages that are regulated by FMRP are associated with autism including those encoding neuroligins, neurexins, Arc, SAPAP4, SHANK3, PSD95, CYFIP and others (Darnell et al., 2011).”
BackgroundGenetic Heritability and Shared Environmental Factors Among Twin Pairs With Autism
Hallmayer, J. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.76 · Cited by 1,970 · cited 3×
“Neurobiology of Autism Autism is a highly genetic disorder and heritability is reported to be moderate to high (Hallmayer et al., 2011; Ronald & Hoekstra, 2011) and shared environmental factor are also important (Hallmayer et al., 2011).”
BackgroundAdvances in autism genetics: on the threshold of a new neurobiology
Abrahams, B. S., & Geschwind, D. H. (2008) · Nature Reviews Genetics · doi:10.1038/nrg2346 · Cited by 1,866 · cited 1×
“…proportion of ASD cannot be explained by single-gene models, these models represent a means of understanding the underlying neurobiology of autism (Abrahams & Geschwind, 2008) and they include fragile X syndrome (FXS) (Hatton et al., 2006), Tuberous Sclerosis (Wiznitzer, 2004), Rett syndrome…”
BackgroundMutations of the X-linked genes encoding neuroligins NLGN3 and NLGN4 are associated with autism
Study, P. A. R. I. S., Jamain, S., Quach, H., Betancur, C., Råstam, M., Colineaux, C., Gillberg, I. C., Soderstrom, H., Giros, B., Leboyer, M., et al. (2003) · Nature Genetics · doi:10.1038/ng1136 · Cited by 1,851 · cited 2×
“Other studies have shown that mutations in synaptic proteins including neuroligins (Glessner et al., 2009; Jamain et al., 2003) and neurexins (Arking et al., 2008; Kim et al., 2008) are associated with autism.”
BackgroundResultAutism genome-wide copy number variation reveals ubiquitin and neuronal genes
Glessner, J. T., Wang, K., Cai, G., Korvatska, O., Kim, C. E., Wood, S., Zhang, H., Estes, A., Brune, C. W., Bradfield, J. P., et al. (2009) · Nature · doi:10.1038/nature07953 · Cited by 1,421 · cited 2×
“Other studies have shown that mutations in synaptic proteins including neuroligins (Glessner et al., 2009; Jamain et al., 2003) and neurexins (Arking et al., 2008; Kim et al., 2008) are associated with autism.”
BackgroundResultDavis, N. O., & Carter, A. S. (2008) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-007-0512-z · Cited by 1,212
The neurobiology of attachment
Insel, T. R., & Young, L. J. (2001) · Nature Reviews Neuroscience · doi:10.1038/35053579 · Cited by 1,173 · cited 1×
“Oxytocin is believed to facilitate human social interactions such as social learning (Insel & Young, 2001) and social memory (Ferguson, Young & Insel, 2002).”
BackgroundThe impact of behaviour problems on caregiver stress in young people with autism spectrum disorders
Lecavalier, L., Leone, S., & Wiltz, J. (2006) · Journal of Intellectual Disability Research · doi:10.1111/j.1365-2788.2005.00732.x · Cited by 1,163
Ressler, K. J., Rothbaum, B. O., Tannenbaum, L., Anderson, P., Graap, K., Zimand, E., Hodges, L., & Davis, M. (2004) · Archives of General Psychiatry · doi:10.1001/archpsyc.61.11.1136 · Cited by 1,063 · cited 2×
“…and there is some evidence that it is effective as an adjunctive therapy to cognitive behavioral therapy for social phobia (Hofmann et al., 2006), acrophobia (Ressler et al., 2004), obsessive compulsive disorder (Kushner et al., 2007) and post traumatic stress disorder (Heresco-Levy et al., 2002).”
BackgroundFragile X Syndrome: Loss of Local mRNA Regulation Alters Synaptic Development and Function
Bassell, G. J., & Warren, S. T. (2008) · Neuron · doi:10.1016/j.neuron.2008.10.004 · Cited by 1,051
Common genetic variants on 5p14.1 associate with autism spectrum disorders
Wang, K., Zhang, H., Ma, D., Bucan, M., Glessner, J. T., Abrahams, B. S., Salyakina, D., Imielinski, M., Bradfield, J. P., Sleiman, P. M. A., et al. (2009) · Nature · doi:10.1038/nature07999 · Cited by 989 · cited 1×
“One of the largest genome-wide association studies found a variant in the intergenic region between CDH 9 and CDH 10 (encoding cadherins 9 and 10) associated with ASDs in families (Wang et al., 2009).”
BackgroundPrevalence of autism-spectrum conditions: UK school-based population study
Baron-Cohen, S., Scott, F. J., Allison, C., Williams, J., Bolton, P., Matthews, F. E., & Brayne, C. (2009) · British Journal of Psychiatry · doi:10.1192/bjp.bp.108.059345 · Cited by 918
Linkage, association, and gene-expression analyses identify CNTNAP2 as an autism-susceptibility gene
Alarcón, M., Abrahams, B. S., Stone, J. L., Duvall, J. A., Perederiy, J. V., Bomar, J. M., Sebat, J., Wigler, M., Martin, C. L., Ledbetter, D. H., et al. (2008) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2007.09.005 · Cited by 818 · cited 1×
“This association was documented in several studies in various populations (Alarcón et al., 2008; Bakkaloglu et al., 2008; Li et al., 2010].”
ResultPsychiatric and psychosocial problems in adults with normal-intelligence autism spectrum disorders
Hofvander, B., Delorme, R., Chaste, P., Nydén, A., Wentz, E., Ståhlberg, O., Herbrecht, E., Stopin, A., Anckarsäter, H., Gillberg, C., et al. (2009) · BMC Psychiatry · doi:10.1186/1471-244x-9-35 · Cited by 812 · cited 1×
“There is evidence that adults with ASDs are at high risk for psychopathology (Hofvander et al., 2009).”
BackgroundOxytocin Infusion Reduces Repetitive Behaviors in Adults with Autistic and Asperger's Disorders
Hollander, E., Novotny, S., Hanratty, M., Yaffe, R., DeCaria, C. M., Aronowitz, B. R., & Mosovich, S. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300021 · Cited by 689 · cited 1×
“In a double blind placebo controlled study, Hollander et al. (2003) showed that oxytocin infusion reduced repetitive behaviors in adults with autism and Asperger Disorder.”
BackgroundLevy, S. E., Mandell, D. S., & Schultz, R. T. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61376-3 · Cited by 651
Autism spectrum disorders and autistic traits: A decade of new twin studies
Ronald, A., & Hoekstra, R. A. (2011) · American Journal of Medical Genetics Part B: Neuropsychiatric Genetics · doi:10.1002/ajmg.b.31159 · Cited by 616 · cited 1×
“Neurobiology of Autism Autism is a highly genetic disorder and heritability is reported to be moderate to high (Hallmayer et al., 2011; Ronald & Hoekstra, 2011) and shared environmental factor are also important (Hallmayer et al., 2011).”
BackgroundJacquemont, S., Curie, A., des Portes, V., Torrioli, M. G., Berry-Kravis, E., Hagerman, R. J., Ramos, F. J., Cornish, K., He, Y., Paulding, C., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3001708 · Cited by 609 · cited 1×
“A controlled trial of AFQ056, another mGluR5 antagonist, was also carried out in Europe and lead to significant improvements in behavior in adults with FXS who had a full mutation that was fully methylated (Jacquemont et al., 2011).”
BackgroundSelf-citationThe Fragile X Syndrome Protein Represses Activity-Dependent Translation through CYFIP1, a New 4E-BP
Napoli, I., Mercaldo, V., Boyl, P. P., Eleuteri, B., Zalfa, F., De Rubeis, S., Di Marino, D., Mohr, E., Massimi, M., Falconi, M., et al. (2008) · Cell · doi:10.1016/j.cell.2008.07.031 · Cited by 609
Arking, D. E., Cutler, D. J., Brune, C. W., Teslovich, T. M., West, K., Ikeda, M., Rea, A., Guy, M., Lin, S., Cook, E. H., et al. (2008) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2007.09.015 · Cited by 590 · cited 2×
“Other studies have shown that mutations in synaptic proteins including neuroligins (Glessner et al., 2009; Jamain et al., 2003) and neurexins (Arking et al., 2008; Kim et al., 2008) are associated with autism.”
BackgroundResultDisruption of neurexin 1 associated with autism spectrum disorder
Kim, H.-G., Kishikawa, S., Higgins, A. W., Seong, I.-S., Donovan, D. J., Shen, Y., Lally, E., Weiss, L. A., Najm, J., Kutsche, K., et al. (2008) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2007.09.011 · Cited by 578
Augmentation of Exposure Therapy With D-Cycloserine for Social Anxiety Disorder
Hofmann, S. G., Meuret, A. E., Smits, J. A. J., Simon, N. M., Pollack, M. H., Eisenmenger, K., Shiekh, M., & Otto, M. W. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.3.298 · Cited by 560 · cited 2×
“…of extinction learning and there is some evidence that it is effective as an adjunctive therapy to cognitive behavioral therapy for social phobia (Hofmann et al., 2006), acrophobia (Ressler et al., 2004), obsessive compulsive disorder (Kushner et al., 2007) and post traumatic stress disorder…”
BackgroundBakkaloglu, B., O'Roak, B. J., Louvi, A., Gupta, A. R., Abelson, J. F., Morgan, T. M., Chawarska, K., Klin, A., Ercan-Sencicek, A. G., Stillman, A. A., et al. (2008) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2007.09.017 · Cited by 537
Pardo, C. A., & Eberhart, C. G. (2007) · Brain Pathology · doi:10.1111/j.1750-3639.2007.00102.x · Cited by 514
King, B. H., Hollander, E., Sikich, L., McCracken, J. T., Scahill, L., Bregman, J. D., Donnelly, C. L., Anagnostou, E., Dukes, K., Sullivan, L., et al. (2009) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2009.30 · Cited by 482
Mitochondrial dysfunction in autism
Giulivi, C., Zhang, Y.-F., Omanska-Klusek, A., Ross-Inta, C., Wong, S., Hertz-Picciotto, I., Tassone, F., & Pessah, I. N. (2010) · JAMA · doi:10.1001/jama.2010.1706 · Cited by 466
Bilousova, T. V., Dansie, L., Ngo, M., Aye, J., Charles, J. R., Ethell, D. W., & Ethell, I. M. (2009) · Journal of Medical Genetics · doi:10.1136/jmg.2008.061796 · Cited by 465 · cited 1×
“The KO mouse studies have shown that minocycline treatment for one month after birth normalized the dendritic spine defects and improved behavior and cognition in these fragile X mice (Bilousova et al., 2009).”
BackgroundSilverman, J. L., Tolu, S. S., Barkan, C. L., & Crawley, J. N. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2009.201 · Cited by 438
Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD)
Williams, K., Brignell, A., Randall, M., Silove, N., & Hazell, P. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004677.pub3 · Cited by 415
A pilot open label, single dose trial of fenobam in adults with fragile X syndrome
Berry-Kravis, E., Hessl, D., Coffey, S., Hervey, C., Schneider, A., Yuhas, J., Hutchison, J., Snape, M., Tranfaglia, M., Nguyen, D. V., et al. (2009) · Journal of Medical Genetics · doi:10.1136/jmg.2008.063701 · Cited by 411 · cited 2×
“…and fenobam which has been around for many years and recently discovered to be an mGluR5 antagonist was tried in a single dose open label study and found to not have significant side effects and also improve the deficits in prepulse inhibition in 12 adults with FXS (Berry-Kravis et al., 2009).”
BackgroundSelf-citationAutistic behavior in children with fragile X syndrome: Prevalence, stability, and the impact of FMRP
Hatton, D. D., Sideris, J., Skinner, M., Mankowski, J., Bailey, D. B., Roberts, J., & Mirrett, P. (2006) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.31286 · Cited by 359 · cited 2×
“Although available data suggest that a large proportion of ASD cannot be explained by single-gene models, these models represent a means of understanding the underlying neurobiology of autism (Abrahams & Geschwind, 2008) and they include fragile X syndrome (FXS) (Hatton et al., 2006), Tuberous Sclerosis (Wiznitzer, 20…”
BackgroundA Systematic Review of Medical Treatments for Children With Autism Spectrum Disorders
McPheeters, M. L., Warren, Z., Sathe, N., Bruzek, J. L., Krishnaswami, S., Jerome, R. N., & Veenstra-VanderWeele, J. (2011) · Pediatrics · doi:10.1542/peds.2011-0427 · Cited by 356
FARZIN, F., PERRY, H., HESSL, D., LOESCH, D., COHEN, J., BACALMAN, S., GANE, L., TASSONE, F., HAGERMAN, P., & HAGERMAN, R. (2006) · Journal of Developmental & Behavioral Pediatrics · doi:10.1097/00004703-200604002-00012 · Cited by 325 · cited 1×
“In childhood a subgroup of premutation carriers particularly boys have ADHD and ASD, the latter in 10% or higher if they present as probands (Farzin et al., 2006).”
BackgroundSelf-citationDecreased expression of the GABAA receptor in fragile X syndrome
D'Hulst, C., De Geest, N., Reeve, S. P., Van Dam, D., De Deyn, P. P., Hassan, B. A., & Kooy, R. F. (2006) · Brain Research · doi:10.1016/j.brainres.2006.08.115 · Cited by 318 · cited 2×
“Another dysfunctional neurotransmitter system in FXS is the GABA system and 8 out of 18 known GABA subunits are significantly reduced in the cortex of the KO mice (D’Hulst et al., 2006).”
BackgroundRescue of behavioral phenotype and neuronal protrusion morphology in Fmr1 KO mice
de Vrij, F. M. S., Levenga, J., van der Linde, H. C., Koekkoek, S. K., De Zeeuw, C. I., Nelson, D. L., Oostra, B. A., & Willemsen, R. (2008) · Neurobiology of Disease · doi:10.1016/j.nbd.2008.04.002 · Cited by 313
Leigh, M. J. S., Nguyen, D. V., Mu, Y., Winarni, T. I., Schneider, A., Chechi, T., Polussa, J., Doucet, P., Tassone, F., Rivera, S. M., et al. (2013) · Journal of Developmental & Behavioral Pediatrics · doi:10.1097/dbp.0b013e318287cd17 · Cited by 298
Self-citationQin, M., Kang, J., Burlin, T. V., Jiang, C., & Smith, C. B. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.0093-05.2005 · Cited by 263
Open-label add-on treatment trial of minocycline in fragile X syndrome.
Paribello, C., Tao, L., Folino, A., Berry-Kravis, E., Tranfaglia, M., Ethell, I. M., & Ethell, D. W. (2010) · BMC Neurology · doi:10.1186/1471-2377-10-91 · Cited by 223 · cited 2×
“$w aterm ark-text $w aterm ark-text $w aterm ark-text minocycline in adolescents and young adults with FXS demonstrated improvements in behavior (Paribello et al., 2010).”
BackgroundOpen-Label Treatment Trial of Lithium to Target the Underlying Defect in Fragile X Syndrome
Berry-Kravis, E., Sumis, A., Hervey, C., Nelson, M., Porges, S. W., Weng, N., Weiler, I. J., & Greenough, W. T. (2008) · Journal of Developmental & Behavioral Pediatrics · doi:10.1097/dbp.0b013e31817dc447 · Cited by 215 · cited 3×
“Lithium is also a targeted treatment in FXS because it can down-regulate mGluR5 signaling by inhibiting inositol phosphate turnover thereby attenuating phospholipase C activity and inhibiting glycogen synthase kinase 3β (GSK3β) (Berry-Kravis et al., 2008).”
BackgroundInfluentialWiznitzer, M. (2004) · Journal of Child Neurology · doi:10.1177/08830738040190090701 · Cited by 214
Casey, J. P., Magalhaes, T., Conroy, J. M., Regan, R., Shah, N., Anney, R., Shields, D. C., Abrahams, B. S., Almeida, J., Bacchelli, E., et al. (2012) · Human Genetics · doi:10.1007/s00439-011-1094-6 · Cited by 200 · cited 1×
“Using this strategy authors are able to identify many new ASD candidate genes and replicate some older ones (Casey et al., 2012), and they suggested this approach as a promising development to evaluate genome wide association data.”
BackgroundAlteration of Plasma Glutamate and Glutamine Levels in Children with High-Functioning Autism
Shimmura, C., Suda, S., Tsuchiya, K. J., Hashimoto, K., Ohno, K., Matsuzaki, H., Iwata, K., Matsumoto, K., Wakuda, T., Kameno, Y., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0025340 · Cited by 189 · cited 1×
“Plasma levels of glutamate and glutamine were found to be high in highfunctioning children with autism (Shimmura et al., 2011).”
BackgroundFMRP Acts as a Key Messenger for Dopamine Modulation in the Forebrain
Wang, H., Wu, L.-J., Kim, S. S., Lee, F. J. S., Gong, B., Toyoda, H., Ren, M., Shang, Y.-Z., Xu, H., Liu, F., et al. (2008) · Neuron · doi:10.1016/j.neuron.2008.06.027 · Cited by 186
Fragile X: Leading the Way for Targeted Treatments in Autism
Wang, L. W., Berry-Kravis, E., & Hagerman, R. J. (2010) · Neurotherapeutics · doi:10.1016/j.nurt.2010.05.005 · Cited by 176
Self-citationMultiple rare variants in the etiology of autism spectrum disorders
Buxbaum, J. D. (2009) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2009.11.1/jdbuxbaum · Cited by 158 · cited 1×
“Although new strategies to identify common genetic risk variants are being applied currently, there is no single model that explains all of the phenotypic variation in cases with autism (Buxbaum, 2009).”
BackgroundEffects of intranasal oxytocin on social anxiety in males with fragile X syndrome
Hall, S. S., Lightbody, A. A., McCarthy, B. E., Parker, K. J., & Reiss, A. L. (2012) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2011.07.020 · Cited by 143 · cited 1×
“In another study, Hall et al. (2012) demonstrated that intranasal oxytocin helps with social anxiety in children with FXS.”
BackgroundPilot-controlled trial of D-cycloserine for the treatment of post-traumatic stress disorder
Heresco-Levy, U., Kremer, I., Javitt, D. C., Goichman, R., Reshef, A., Blanaru, M., & Cohen, T. (2002) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145702003061 · Cited by 134
Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD)
Williams, K., Wheeler, D. M., Silove, N., & Hazell, P. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004677.pub2 · Cited by 131
De Rubeis, S., & Bagni, C. (2010) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2009.09.013 · Cited by 126 · cited 1×
“The overlap between autism and FXS relates to the many functions of FMRP that is absent or deficient in FXS. FMRP binds, stabilizes and transports to the synapse hundreds of mRNAs important for synaptic plasticity (Bassell & Warren, 2008; De Rubeis & Bagni, 2010).”
BackgroundChonchaiya, W., Au, J., Schneider, A., Hessl, D., Harris, S. W., Laird, M., Mu, Y., Tassone, F., Nguyen, D. V., & Hagerman, R. J. (2012) · Human Genetics · doi:10.1007/s00439-011-1106-6 · Cited by 109 · cited 1×
“The presence of seizures in children with the premutation can exacerbate autism symptoms so seizures should be treated vigorously in these patients (Chonchaiya et al., 2012).”
BackgroundSelf-citationUtari, A., Chonchaiya, W., Rivera, S. M., Schneider, A., Hagerman, R. J., Faradz, S. M. H., Ethell, I. M., & Nguyen, D. V. (2010) · American Journal on Intellectual and Developmental Disabilities · doi:10.1352/1944-7558-115.5.433 · Cited by 105
Self-citationRegulation of molecular pathways in the Fragile X Syndrome: insights into Autism Spectrum Disorders
De Rubeis, S., & Bagni, C. (2011) · Journal of Neurodevelopmental Disorders · doi:10.1007/s11689-011-9087-2 · Cited by 73 · cited 2×
“FMRP regulates both basal and activity-dependent local protein synthesis at the synapse (De Rubeis & Bagni, 2011; Napoli et al., 2008).”
BackgroundModi, M. E., & Young, L. J. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.01.026 · Cited by 47 · cited 3×
“In childhood a subgroup of premutation carriers particularly boys have ADHD and ASD, the latter in 10% or higher if they present as probands (Farzin et al., 2006).”
Method
Cited by
Oxytocin and vasopressin systems in genetic syndromes and neurodevelopmental disorders
Francis, S. M., Sagar, A., Levin-Decanini, T., Liu, W., Carter, C. S., & Jacob, S. (2014) · Brain Research · doi:10.1016/j.brainres.2014.01.021 · Cited by 101
Thurman, A. J., McDuffie, A., Hagerman, R., & Abbeduto, L. (2014) · Research in Developmental Disabilities · doi:10.1016/j.ridd.2014.01.032 · Cited by 70
“More generally, the symptom overlap between FXS and nonsyndromic ASD has led to the hope that targeted treatments benefitting FXS will also benefit those with nonsyndromic ASD (Gurkan & Hagerman, 2012).”
Self-citationDendritic spine actin cytoskeleton in autism spectrum disorder
Joensuu, M., Lanoue, V., & Hotulainen, P. (2018) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2017.08.023 · Cited by 65
Developing new pharmacotherapies for autism
Ecker, C., Spooren, W., & Murphy, D. (2013) · Journal of Internal Medicine · doi:10.1111/joim.12113 · Cited by 31
Metadata
- Authors
- Gürkan, C. K., & Hagerman, R. J.
- Venue
- Research in Autism Spectrum Disorders
- Publisher
- Elsevier BV
- Published
- 2012-10
- Volume
- 6
- Issue
- 4
- Pages
- 1311-1320
- ISSN
- 1878-0237 (ISSN-L)
- 1750-9467
- OpenAlex
- W2058438630
- Cited by
- 44
- References
- 54
- FWCI
- 5.31
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.